Skip to content Skip to footer
team-wissel

M.D.

Prof. Jörg Wissel

Prof. Jörg Wissel, MD, FRCP is a specialist in Neurorehabilitation, Movement Disorders and Botulinumtoxin treatment. He is a board certified Neurologist, Rehabilitation specialist and Psychotherapist and authored more than 125 original articles.

Germany

Biography

Prof. Jörg Wissel, MD, FRCP is a specialist in Neurorehabilitation, Movement Disorders and Botulinumtoxin treatment. He is a board certified Neurologist, Rehabilitation specialist and Psychotherapist and authored more than 125 original articles.

Since 2012 he is the head of the Department Neurorehabilitation and Physical Therapy at Vivantes Hospital Spandau in Berlin, Germany. Since 2000 he is Professor of Neurology and member of the faculty at University of Innsbruck, Austria. Since 2010 he is also Professor of Neurology at University of Potsdam, Germany.

He was Member of the Board of the German Neurorehabilitation Society, scientific advisor of the German Dystonia Society (patient association) and was past chairman of the German Botulinumtoxin User Group of the German Society of Neurology.

Supported by Merz Therapeutics GmbH

Liability for links
Our site contains links to external websites, over which we have no control. Therefore we cannot accept any responsibility for this external content. The respective provider or operator is always responsible for the contents of any linked site. At the time of linking the linked sites where checked for possible legal violations. At the time of linking illegal contents were not indicated. A permanent control of the linked pages is unreasonable without concrete evidence of violation. Upon notification of violations, we will remove such links immediately.

Award scoring criteria

The following criteria will be judged out of a score of 5; (1 is suboptimal; 2 is adequate; 3 is good; 4 is very good; 5 is excellent)

GENERAL

  • Days per week working in spasticity management
  • Average number of spasticity patients managed per month
  • Environment and clinical team (type of institution, location, size/structure of clinical team, particular patient needs)
  • Role of responsibility in managing patients with spasticity
  • Scientific appointments in spasticity
  • Honours for work undertaken in spasticity

SCHOLARLY

  • Number of research projects investigating relevant aspects of spasticity management
  • Impact of research projects investigating relevant aspects of spasticity management
  • Number of peer-reviewed publications on topic
    Number of presentations of research at international meetings
  • Number of presentations at national conferences
  • Teaching/mentorship of younger injectors
  • h-index

CLINICAL

  • Evidence of development or growth of a spasticity program at the applicant’s practice or institution
  • Breadth of services provided, including medications, toxins, physical interventions, and Intrathecal Baclofen Therapy (ITB)
  • Role of responsibility in managing patients with spasticity

ENDORSEMENT

  • Endorsed by senior peer

In the event of a tie, based on the above scoring criteria, the Toxnet Co-Chairs will make the final decision.